{
  "data": {
    "indicator": {
      "slug": "ctgov-glp1-trial-starts",
      "name": "GLP-1, incretin multi-agonist and amylin trial starts",
      "definition": "Count of interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.",
      "unit": "count",
      "scale": "1",
      "default_unit": "count",
      "default_scale": "1"
    },
    "scale": "1",
    "unit": "count",
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "points": [
      {
        "period_start": "2020-01-01",
        "period_label": "2020",
        "value": 66,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_D57AYJHKXY4NNKXD2SVTK32EAA",
        "url": "https://statorigin.org/stat/stat_D57AYJHKXY4NNKXD2SVTK32EAA",
        "source_org": "ClinicalTrials.gov",
        "source": {
          "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
          "org_short_name": "ClinicalTrials.gov",
          "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in any country",
          "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2020-01-01%2C2020-12-31%5D&countTotal=true&pageSize=1&fields=NCTId",
          "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in any country.",
          "published_date": null
        }
      },
      {
        "period_start": "2021-01-01",
        "period_label": "2021",
        "value": 101,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_7104546TADZV3662S5Q9YBAEWE",
        "url": "https://statorigin.org/stat/stat_7104546TADZV3662S5Q9YBAEWE",
        "source_org": "ClinicalTrials.gov",
        "source": {
          "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
          "org_short_name": "ClinicalTrials.gov",
          "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in any country",
          "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2021-01-01%2C2021-12-31%5D&countTotal=true&pageSize=1&fields=NCTId",
          "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in any country.",
          "published_date": null
        }
      },
      {
        "period_start": "2022-01-01",
        "period_label": "2022",
        "value": 104,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_1DF2Y1EZX04WP9SJ06VED4HDNX",
        "url": "https://statorigin.org/stat/stat_1DF2Y1EZX04WP9SJ06VED4HDNX",
        "source_org": "ClinicalTrials.gov",
        "source": {
          "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
          "org_short_name": "ClinicalTrials.gov",
          "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in any country",
          "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2022-01-01%2C2022-12-31%5D&countTotal=true&pageSize=1&fields=NCTId",
          "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in any country.",
          "published_date": null
        }
      },
      {
        "period_start": "2023-01-01",
        "period_label": "2023",
        "value": 142,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_VZB9SG9NPYJG775T2JB8T56H2Q",
        "url": "https://statorigin.org/stat/stat_VZB9SG9NPYJG775T2JB8T56H2Q",
        "source_org": "ClinicalTrials.gov",
        "source": {
          "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
          "org_short_name": "ClinicalTrials.gov",
          "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in any country",
          "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2023-12-31%5D&countTotal=true&pageSize=1&fields=NCTId",
          "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in any country.",
          "published_date": null
        }
      },
      {
        "period_start": "2023-01-01",
        "period_label": "1 Jan 2023 to 27 Sep 2026",
        "value": 798,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_XHPSW4TF36XP92G2FBWQ9FK1ER",
        "url": "https://statorigin.org/stat/stat_XHPSW4TF36XP92G2FBWQ9FK1ER",
        "source_org": "ClinicalTrials.gov",
        "source": {
          "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
          "org_short_name": "ClinicalTrials.gov",
          "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in any country",
          "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId",
          "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in any country.",
          "published_date": null
        }
      },
      {
        "period_start": "2024-01-01",
        "period_label": "2024",
        "value": 191,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_5KY3BKYS7748Y65S7AVS6JM8GP",
        "url": "https://statorigin.org/stat/stat_5KY3BKYS7748Y65S7AVS6JM8GP",
        "source_org": "ClinicalTrials.gov",
        "source": {
          "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
          "org_short_name": "ClinicalTrials.gov",
          "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in any country",
          "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2024-01-01%2C2024-12-31%5D&countTotal=true&pageSize=1&fields=NCTId",
          "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in any country.",
          "published_date": null
        }
      },
      {
        "period_start": "2025-01-01",
        "period_label": "2025",
        "value": 223,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_7JM6D3W14VX69200KCXH1HH68C",
        "url": "https://statorigin.org/stat/stat_7JM6D3W14VX69200KCXH1HH68C",
        "source_org": "ClinicalTrials.gov",
        "source": {
          "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
          "org_short_name": "ClinicalTrials.gov",
          "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in any country",
          "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D&countTotal=true&pageSize=1&fields=NCTId",
          "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in any country.",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "GLOBAL",
      "CN",
      "US"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 7
  }
}